• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液透析清除普罗帕酮。

Hemodialysis removal of propafenone.

作者信息

Burgess E D, Duff H J

机构信息

Department of Medicine, University of Calgary, Alberta, Canada.

出版信息

Pharmacotherapy. 1989;9(5):331-3. doi: 10.1002/j.1875-9114.1989.tb04145.x.

DOI:10.1002/j.1875-9114.1989.tb04145.x
PMID:2813154
Abstract

Propafenone kinetics were studied after intravenous and oral dosing in a patient with end-stage renal disease. Hemodialysis was performed within 10 hours of dosing in order to assess its effects. After intravenous administration of 70 mg propafenone, total-body clearance was 10.5 ml/min/kg before and 10.4 ml/min/kg during hemodialysis. After a single oral dose of 300 mg, clearance was 19.4 ml/min/kg before and 18.9 ml/min/kg during hemodialysis. Bioavailability was 48%.

摘要

在一名终末期肾病患者中,研究了静脉注射和口服普罗帕酮后的动力学情况。给药后10小时内进行血液透析,以评估其效果。静脉注射70毫克普罗帕酮后,血液透析前全身清除率为10.5毫升/分钟/千克,血液透析期间为10.4毫升/分钟/千克。单次口服300毫克后,血液透析前清除率为19.4毫升/分钟/千克,血液透析期间为18.9毫升/分钟/千克。生物利用度为48%。

相似文献

1
Hemodialysis removal of propafenone.血液透析清除普罗帕酮。
Pharmacotherapy. 1989;9(5):331-3. doi: 10.1002/j.1875-9114.1989.tb04145.x.
2
Bioavailability and kinetics of cibenzoline in patients with normal and impaired renal function.
J Clin Pharmacol. 1991 Jan;31(1):38-44. doi: 10.1002/j.1552-4604.1991.tb01884.x.
3
Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.利福平治疗对CYP2D6快代谢型和慢代谢型患者中普罗帕酮处置的影响。
Pharmacogenetics. 1999 Oct;9(5):551-9.
4
Propafenone disposition in renal insufficiency and renal failure.普罗帕酮在肾功能不全和肾衰竭中的处置
J Clin Pharmacol. 1989 Feb;29(2):112-3. doi: 10.1002/j.1552-4604.1989.tb03296.x.
5
Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response.静脉注射和口服普罗帕酮治疗婴幼儿心动过速:药代动力学与临床反应
J Clin Pharmacol. 1998 Jun;38(6):496-501. doi: 10.1002/j.1552-4604.1998.tb05786.x.
6
Busulfan clearance in renal failure and hemodialysis.
Bone Marrow Transplant. 2000 Jan;25(2):201-3. doi: 10.1038/sj.bmt.1702112.
7
Tissue distribution of propafenone in the rat after intravenous administration.静脉注射后普罗帕酮在大鼠体内的组织分布。
Eur J Drug Metab Pharmacokinet. 1991 Jan-Mar;16(1):23-7. doi: 10.1007/BF03189870.
8
Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.
Kidney Int. 1984 Sep;26(3):308-18. doi: 10.1038/ki.1984.174.
9
Intravenous versus oral initial load of propafenone for conversion of recent-onset atrial fibrillation in the emergency room: a randomized trial.急诊室中普罗帕酮静脉注射与口服首剂负荷量用于近期发作房颤转复的随机试验
Ital Heart J. 2000 Jul;1(7):475-9.
10
Intraperitoneal administration of acyclovir in patients receiving continuous ambulatory peritoneal dialysis.接受持续性非卧床腹膜透析的患者腹腔内给予阿昔洛韦。
J Clin Pharmacol. 1990 Nov;30(11):997-1000. doi: 10.1002/j.1552-4604.1990.tb03585.x.

引用本文的文献

1
Full recovery after prolonged resuscitation from cardiac arrest due to propafenone intoxication: A case report.普罗帕酮中毒致心脏骤停长时间复苏后完全康复:一例报告
Medicine (Baltimore). 2018 Apr;97(15):e0285. doi: 10.1097/MD.0000000000010285.
2
Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.持续肾脏替代治疗患者的药物剂量。药代动力学及治疗方面的考量。
Clin Pharmacokinet. 1993 May;24(5):362-79. doi: 10.2165/00003088-199324050-00002.
3
Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.
普罗帕酮。对其药理学、药代动力学及在心律失常治疗中的应用的重新评估。
Drugs. 1993 Jan;45(1):85-130. doi: 10.2165/00003495-199345010-00008.
4
Clinical pharmacokinetics of propafenone.
Clin Pharmacokinet. 1991 Jul;21(1):1-10. doi: 10.2165/00003088-199121010-00001.